Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eftilagimod Alpha in Combination With Neoadjuvant Chemotherapy in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

NCT07102940 is registered in ClinicalTrials.gov with George Washington University as lead sponsor.

NCT NCT07102940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07102940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eftilagimod Alpha in Combination With Neoadjuvant Chemotherapy in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer
Lead sponsor
George Washington University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
August 31, 2028
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her 2 negative breast cancer, hr positive/her-2 negative breast cancer, stage 1-3